Abstract

Vaccination of SARS-CoV-2 convalescent individuals generates broad and potent antibody responses. Here, we isolate 459 spike-specific monoclonal antibodies (mAbs) from two individuals who were infected with the index variant of SARS-CoV-2 and later boosted with mRNA-1273. We characterize mAb genetic features by sequence assignments to the donors’ personal immunoglobulin genotypes and assess antibody neutralizing activities against index SARS-CoV-2, Beta, Delta, and Omicron variants. The mAbs used a broad range of immunoglobulin heavy chain (IGH) V genes in the response to all sub-determinants of the spike examined, with similar characteristics observed in both donors. IGH repertoire sequencing and B cell lineage tracing at longitudinal time points reveals extensive evolution of SARS-CoV-2 spike-binding antibodies from acute infection until vaccination five months later. These results demonstrate that highly polyclonal repertoires of affinity-matured memory B cells are efficiently recalled by vaccination, providing a basis for the potent antibody responses observed in convalescent persons following vaccination.

Here, the authors isolated and characterized genetic features of spike-specific monoclonal antibodies. They show how the antibodies evolve from infection to after vaccination and conclude that highly polyclonal repertoires of affinity-matured memory B cells are efficiently recalled by vaccination.

Details

Title
Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
Author
Chernyshev, Mark 1   VIAFID ORCID Logo  ; Sakharkar, Mrunal 2 ; Connor, Ruth I. 3   VIAFID ORCID Logo  ; Dugan, Haley L. 2 ; Sheward, Daniel J. 1   VIAFID ORCID Logo  ; Rappazzo, C. G. 2 ; Stålmarck, Aron 1   VIAFID ORCID Logo  ; Forsell, Mattias N. E. 4   VIAFID ORCID Logo  ; Wright, Peter F. 3 ; Corcoran, Martin 1 ; Murrell, Ben 1   VIAFID ORCID Logo  ; Walker, Laura M. 5 ; Karlsson Hedestam, Gunilla B. 1 

 Tumor and Cell Biology, Karolinska Institutet, Department of Microbiology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Adimab LLC, Lebanon, USA (GRID:grid.508569.7) (ISNI:0000 0004 1794 9693) 
 Dartmouth-Hitchcock Medical Center, Department of Pediatrics, Lebanon, USA (GRID:grid.413480.a) (ISNI:0000 0004 0440 749X) 
 Umeå University, Department of Clinical Microbiology, Umeå, Sweden (GRID:grid.12650.30) (ISNI:0000 0001 1034 3451) 
 Adimab LLC, Lebanon, USA (GRID:grid.508569.7) (ISNI:0000 0004 1794 9693); Invivyd Inc, Waltham, USA (GRID:grid.508569.7) 
Pages
2249
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2803110430
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.